My questions about pazopanib

U.S. regulators gave the nod to GlaxoSmithKline Plc's Votrient (pazopanib) for soft-tissue sarcoma on Thursday, the first new drug in decades to treat patients with this type of cancer.

“Votrient, which is already approved for advanced kidney cancer, works by interfering with the growth of new blood vessels that tumors need to survive.

Votrient carries a boxed warning, the most serious kind, about its potential link to liver damage, which can be fatal.”

Votrient is a so-called targeted drug and I have a couple of questions:

1.       What is about hepatotoxicity? Why? Votrient is the targeted drug which should work “targeted” without affecting liver! Again, there is something very wrong with the “targeted” terminology…

2.       Why this “targeted” approach is not used for the development of medicines against lung, breast, prostate and colon cancers where needs are really unmet?

I guess that we know the answer – the targeted approach is completely wrong in oncology and therefore it is not efficient.